The Drug Enforcement Administration has announced its intent to temporarily schedule the synthetic opioid N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide (furanyl fentanyl) into schedule I pursuant to the temporary scheduling provisions of the Controlled Substances Act. The DEA intends to issue a final order effecting this change as soon as possible after Oct. 27, which will mark the end of the 30-day notice period. Upon the issuance of that order, furanyl fentanyl will be subject to the regulatory controls and administrative, civil, and criminal sanctions applicable to the manufacture, distribution, possession, importation, exportation, research, and conduct of instructional activities of schedule I controlled substances. This order will be effective for two years, with a possible extension of one year, pending completion of the regular scheduling process.
According to the DEA, available data and information indicate that this substance has a high potential for abuse, no currently accepted medical use in treatment in the U.S., and a lack of accepted safety for use under medical supervision. Seizures of furanyl fentanyl have been encountered in powder form and in drug paraphernalia commonly associated with heroin or other opioid abuse, including glassine bags, and as a residue on spoons and bottle caps. Furanyl fentanyl has been encountered as a single substance as well as in combination with other substances of abuse, including heroin, fentanyl, butyryl fentanyl, and U-47700.